Arcutis presents ZORYVE (roflumilast) data at EADV and Fall clinical

- Presentation of data from the INTEGUMENT-INFANT trial of investigational ZORYVE cream 0.05% in infants ages 3 to =2-grade improvement from baseline. Additionally, IGA-Scalp Success, defined as a score of 0 (Clear) or 1 (Almost Clear) with a >=2-grade improvement from baseline, was achieved by 67.5% of infants. Caregivers also reported rapid itch improvement, with 46.6% of infants achieving at least a 25% improvement in pruritus (itch) from baseline within 10 minutes of application, as assessed by caregivers, based on the Dynamic Pruritus Scale (DPS-25) (n=88). -- Pattern of Improvement in Scalp Versus Body Psoriasis With Roflumilast Foam 0.3%: An Analysis of the Phase 3 ARRECTOR Trial. M. Gooderham, et al. Fall Clinical Dermatology Conference.In a subanalysis of the Phase 3 trial of 432 patients aged 12 and older, more patients treated with ZORYVE foam 0.3% than vehicle foam achieved clear or almost clear skin at Week 8 on both the scalp (66.4% vs 27.8%) and the body (45.5% vs 20.1%). Within 24 hours of the first application, individuals treated with ZORYVE experienced greater improvement in mean itch scores compared to vehicle (SI-NRS, defined as a patient-reported measure of scalp itch severity: Least-squares mean improvement of 0.44 vs 0.09; WI-NRS, defined as a patient-reported measure of worst itch severity: Least-squares mean improvement of 0.42 vs 0.01). -- Improvements in Psoriasis, Including Sexual Function and Personal Relationships, With Roflumilast Cream 0.3% and Foam 0.3%: Outcomes From the Phase 3 DERMIS-1/2 and ARRECTOR Trials. M. Payette, et al. Fall Clinical Dermatology Conference.This analysis of patients from the DERMIS-1/2 and ARRECTOR studies found that ZORYVE cream 0.3% and foam 0.3% improved psoriasis signs and symptoms and quality of life, along with patient-reported sexual function and personal relationships, through Week 8, in individuals with psoriasis both with and without genital involvement at baseline. -- Tape-strip Proteomic Profiling and Biopsy Validation Highlight Inflammatory Pathogenesis in Seborrheic Dermatitis.E. Guttman, et al.EADV Congress, Poster P2290.Using proteomic analysis of tape strips and skin biopsies from adults with seborrheic dermatitis, this collaborative research identified the inflammatory pathways driving the disease and the skin barrier impairment that distinguishes it from atopic dermatitis, while also highlighting seborrheic dermatitis as a primarily Th17-mediated disease. Real-world topical corticosteroid research: Arcutis will present for the first time real-world survey research developed in collaboration with the National Eczema Association and the National Psoriasis Foundation, alongside a new targeted review of published literature on adverse events associated with topical corticosteroid use. -- Real-World Topical Corticosteroid Treatment Patterns and Perceptions of Disease Control Among Adults and Caregivers of Children With Atopic Dermatitis, Psoriasis, or Seborrheic Dermati